Inve US ▾
AUAUTL

Autolus Therapeutics (AUTL) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 11, 2026

Source: earnings call transcript

Executive summary

Autolus Therapeutics Q2 FY26 — Strong AUCATZYL Sales Growth and Raised Full-Year Guidance

Autolus Therapeutics delivered a strong second quarter, driven by robust AUCATZYL sales growth and significant gross margin improvement, leading to an upward revision of full-year revenue guidance. The company is expanding its commercial footprint in the U.S. and U.K. while advancing a diverse pipeline of oncology and autoimmune programs, supported by a new strategic financing facility. Management anticipates continued momentum and key clinical data readouts in the coming periods.

Highlights

5

  • AUCATZYL net product revenue reached $45.7 million in Q2 FY26, a substantial increase over $26 million in Q1 FY26.

  • First half FY26 AUCATZYL revenue of $71.9 million is close to the full-year revenue of the prior year's launch.

  • Full-year FY26 AUCATZYL revenue guidance raised to $140 million-$150 million, up from $120 million-$135 million.

  • Gross margin improved significantly to 55% in Q2 FY26, up from 6% in Q1 FY26 and negative in prior quarters.

  • Activated over 80 treatment centers by mid-year, exceeding the initial full-year target.

Concerns

2

  • Selling, general and administrative expenses increased to $41.2 million in Q2 FY26, up from $30.3 million in Q2 FY25, partly due to one-time restructuring costs.

  • Net loss for Q2 FY26 was $39.1 million, though an improvement from $47.9 million in Q2 FY25.

Guidance & targets

CategoryTargetConfidence
Full-year AUCATZYL Net Product Revenue
$140M-$150M
high materiality
High
Gross Margin for ALL Business
65%-70%
high materiality
Medium
Activated Treatment Centers (U.S.)
90+ centers
medium materiality
High
Activated Treatment Centers (U.K.)
around 20 centers
medium materiality
High
CATULUS Study (pediatric ALL) Data Readout
First data readout
high materiality
High
CATULUS Study (pediatric ALL) Filing
Filing
high materiality
High
LUMINA Study (lupus nephritis) Data Readout
Data readout
high materiality
High
BOBCAT Study (progressive MS) First Data Update
12 patients data
high materiality
High
BOBCAT Study (progressive MS) Second Data Update
18 patients data with longer follow-up
high materiality
High
Pediatric ALL Launch
Launch
high materiality
Medium
Lupus Indications Launch
Launch
high materiality
Medium
CATULUS Study (pediatric ALL) Enrollment
End of enrollment
medium materiality
High

Segment performance

SegmentRevenueYoYQoQMargin
AUCATZYL (obe-cel) Product Sales
Strong sales growth in Q2 FY26, driven by increased adoption in the U.S. and initial positive momentum in the U.K. Gross margin significantly improved due to higher volumes and operational efficiencies. The company exceeded its mid-year target for activated centers in the U.S. and is expanding its U.K. footprint.
Activated Centers (U.S.): >80Activated Centers (U.K.): approaching 20
$45.7M118.7%75.8%55%

Deals & partnerships

Perceptive Advisors Strategic financing facility Up to $250M in aggregate principal amount 5-year

A 5-year interest-only senior credit facility to provide additional capital for key inflection points and pipeline programs.

Risks & headwinds

Seasonality in AUCATZYL sales Q3 and Q4 FY26

Implied slight decline in Q3/Q4 revenue compared to Q2 based on guidance range.

Mitigation:Management considers seasonality in guidance and expects continued strong underlying demand and activity.

Increased SG&A expenses Q2 FY26

$41.2M in Q2 FY26 vs $30.3M in Q2 FY25

Mitigation:Partially due to one-time termination-related expenses from a strategic operational efficiency and cost reduction initiative, which are largely behind the company.

What to watch in Q3 FY26

AUCATZYL Net Product Revenue

Q3 FY26
Current $45.7M (Q2 FY26)
Target Maintain strong sales momentum, consistent with raised FY26 guidance of $140M-$150M

Why it matters

Verifying continued commercial execution and market adoption, especially given potential seasonality and the significant Q2 step-up.

Very good question. So when we look at the -- obviously, the first half of the year, we see obviously a pretty significant step-up in Q2. We believe that is in part driven by the positive data that was reported from the real-world experience at the TANDEM meeting and certainly did drive a very significant increase in registrations onto the program in the second half of the first quarter. And those -- obviously, those patients obviously were driving to quite an extent, I think, the very positive outcome we've seen in Q2. So we think that creates a very good foundation for the rest of the year. There is certainly going to be elements of seasonality that we would expect during the course of the year. And so given that, certainly, we've seen that to some extent last year. It is an element that we're considering. And we believe that the guidance that we're providing is reasonable and certainly has an element of prudence as well.

Find out whether AUTL delivers this. Inve re-checks your case every morning.

Q&A highlights

The high end of the raised FY26 revenue guidance implies a slight decline in Q3/Q4 compared to Q2. Is this conservatism or expected seasonality/one-timers?

Management confirmed that the Q2 step-up was partly driven by positive real-world data from the TANDEM meeting, leading to increased registrations. They expect elements of seasonality, similar to last year, and the guidance reflects prudence while maintaining confidence in continued activity and demand.

“There is certainly going to be elements of seasonality that we would expect during the course of the year. And so given that, certainly, we've seen that to some extent last year. It is an element that we're considering. And we believe that the guidance that we're providing is reasonable and certainly has an element of prudence as well.”

asked by Salim Syed · answered by Christian Itin

2 min read 5 chapters

Detailed narrative

AUCATZYL Commercial Performance and Market Expansion

Autolus reported strong commercial momentum for AUCATZYL, with Q2 FY26 net product revenue reaching $45.7 million, a significant increase from $26 million in Q1 FY26. First-half revenue totaled $71.9 million, nearly matching the full-year revenue of the prior launch year. This performance led to an upward revision of the full-year FY26 revenue guidance to $140 million-$150 million. The company has expanded its U.S. footprint to over 80 activated centers by mid-year, exceeding its initial full-year target, and expects to reach 90+ centers by year-end. The U.K. launch also shows strong initial adoption, with approximately 20 centers expected to be active by year-end.

Gross Margin Improvement and Profitability Path

Gross margin for AUCATZYL improved substantially to 55% in Q2 FY26, up from 6% in Q1 FY26 and negative in prior quarters. This improvement was driven by increased commercial production volume, operating model efficiencies, and cost reduction initiatives, including consolidating clinical trial manufacturing into the Nucleus facility. Management expects gross margin for the adult ALL business to continue improving towards a target of 65%-70% within 12-18 months, which is a key driver for achieving profitability in this business line.

Pipeline Advancement in Autoimmune and Oncology

Autolus is advancing a diverse pipeline beyond adult ALL. Key upcoming data readouts include an update on the CARLYSLE study in systemic lupus at the ACR conference by year-end, initial data from the AUTO8 program in light-chain amyloidosis by year-end, and additional analyses from the FELIX study. The BOBCAT study in progressive multiple sclerosis is expected to provide initial data from 12 patients in Q1 2027 and a second update from 18 patients with longer follow-up in H2 2027. The pivotal CATULUS study in pediatric ALL is expected to complete enrollment by year-end, with first data by end of 2027 and filing by end of 2027/early 2028. The LUMINA study in lupus nephritis is anticipated to deliver Phase II data in 2028.

Strategic Financing and Cash Runway

The company secured a strategic financing facility with Perceptive Advisors for up to $250 million. An initial $75 million was drawn at closing in July, with an additional $25 million available at option. Further tranches of $150 million are tied to specific revenue milestones. This financing, combined with existing cash and anticipated net revenues, extends Autolus' cash runway into Q2 2028, providing capital to support key clinical data milestones and expansion into new markets.

Manufacturing Capacity and Automation

Autolus is well-positioned from a manufacturing capacity perspective, capable of fully serving the ALL market (adult and pediatric) with its current setup. The Nucleus facility has the ability to mobilize additional clean rooms as needed for future expansion beyond ALL. The manufacturing process is already significantly automated, with plans for another substantial automation upgrade over the next 12-15 months to achieve a very high level of automation and further efficiency gains across the entire production and delivery chain.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.